
The PIONEER 11 trial evaluated oral semaglutide in predominantly Chinese participants with type 2 diabetes uncontrolled by diet and exercise. Semaglutide significantly reduced HbA1c and body weight compared to placebo, with a tolerable safety profile.
Like
Save
Share